Merck KGaA's 2006 results as expected
Darmstadt, Germany-based Merck KGaA posted a strong set of results for full-year 2006. Sales for the group as a whole rose 8.5% on 2005 to 6.26 billion euros ($8.10 billion), largely in line with analysts' consensus forecast. Lehman Brothers, however, predicted income of 6.34 billion euros.
Fourth-quarter 2006 sales for the group as a whole jumped 9.0% to 1.62 billion euros despite negative currency effects, while Merck's full-year operating result rose 25% to 1.10 billion euros, surpassing the previous record high, set in 2005, of 883.0 million euros. Merck's full-year earnings before interest and tax jumped 39% to 1.32 billion euros, while fourth-quarter 2006 EBIT increased 36% to 192.0 million euros. On the day of the news, the firm's share price rose 0.9% to 90.37 euros.
Strong contribution from Rx drug unit
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze